Cargando…

Two independent epigenetic biomarkers predict survival in neuroblastoma

BACKGROUND: Neuroblastoma (NB) is the most common extracranial pediatric solid tumor with a highly variable clinical course, ranging from spontaneous regression to life-threatening disease. Survival rates for high-risk NB patients remain disappointingly low despite multimodal treatment. Thus, there...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yáñez, Yania, Grau, Elena, Rodríguez-Cortez, Virginia C, Hervás, David, Vidal, Enrique, Noguera, Rosa, Hernández, Miguel, Segura, Vanessa, Cañete, Adela, Conesa, Ana, de Mora, Jaime Font, Castel, Victoria
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4357365/ https://www.ncbi.nlm.nih.gov/pubmed/25767620 http://dx.doi.org/10.1186/s13148-015-0054-8

Ejemplares similares

TIAM1 variants improve clinical outcome in neuroblastoma
por: Sanmartín, Elena, et al.
Publicado: (2017)

Targeting Neuroblastoma Stem Cells with Retinoic Acid and Proteasome Inhibitor
por: Hämmerle, Barbara, et al.
Publicado: (2013)

Clinical Features of Neuroblastoma With 11q Deletion: An Increase in Relapse Probabilities In Localized And 4S Stages
por: J Ribelles, Antonio, et al.
Publicado: (2019)

Publisher Correction: Clinical Features of Neuroblastoma With 11q Deletion: An Increase in Relapse Probabilities In Localized And 4S Stages
por: Juan Ribelles, Antonio, et al.
Publicado: (2020)

MTHFR and VDR Polymorphisms Improve the Prognostic Value of MYCN Status on Overall Survival in Neuroblastoma Patients
por: Olivera, Gladys G., et al.
Publicado: (2020)

Intratumoral immunosuppression profiles in 11q‐deleted neuroblastomas provide new potential therapeutic targets
por: Coronado, Esther, et al.
Publicado: (2021)

Next-Generation Sequencing Identifies Potential Actionable Targets in Paediatric Sarcomas
por: Juan Ribelles, Antonio, et al.
Publicado: (2021)

Pharmacogenetics in Neuroblastoma: What Can Already Be Clinically Implemented and What Is Coming Next?
por: Olivera, Gladys G., et al.
Publicado: (2021)

Evaluation of circulating tumor DNA by electropherogram analysis and methylome profiling in high-risk neuroblastomas
por: Trinidad, Eva María, et al.
Publicado: (2023)

Pharmacogenetics implementation in the clinics: information and guidelines for germline variants
por: Olivera, Gladys, et al.
Publicado: (2019)

Retinoblastoma and mosaic 13q deletion: a case report
por: Gargallo, Pablo, et al.
Publicado: (2021)

Germline Predisposition to Pediatric Cancer, from Next Generation Sequencing to Medical Care
por: Gargallo, Pablo, et al.
Publicado: (2021)

Neuroblastoma after Childhood: Prognostic Relevance of Segmental Chromosome Aberrations, ATRX Protein Status, and Immune Cell Infiltration()
por: Berbegall, Ana P., et al.
Publicado: (2014)

Liquidhope: methylome and genomic profiling from very limited quantities of plasma-derived DNA
por: Trinidad, Eva María, et al.
Publicado: (2023)

Vitronectin as a molecular player of the tumor microenvironment in neuroblastoma
por: Burgos-Panadero, Rebeca, et al.
Publicado: (2019)

How to minimise the effect of tumour cell content in detection of aberrant genetic markers in neuroblastoma
por: Piqueras, M, et al.
Publicado: (2011)

Lymph microvascularization as a prognostic indicator in neuroblastoma
por: Tadeo, Irene, et al.
Publicado: (2018)

Exosomal microRNAs from Longitudinal Liquid Biopsies for the Prediction of Response to Induction Chemotherapy in High-Risk Neuroblastoma Patients: A Proof of Concept SIOPEN Study (‖)
por: Morini, Martina, et al.
Publicado: (2019)

miR‐200c and phospho‐AKT as prognostic factors and mediators of osteosarcoma progression and lung metastasis
por: Berlanga, Pablo, et al.
Publicado: (2016)

Epigenetic therapies for neuroblastoma: immunogenicity awakens
por: Jiménez, Carlos, et al.
Publicado: (2023)

Targeting of epigenetic regulators in neuroblastoma
por: Jubierre, Luz, et al.
Publicado: (2018)

Intra-Tumour Genetic Heterogeneity and Prognosis in High-Risk Neuroblastoma
por: López-Carrasco, Amparo, et al.
Publicado: (2021)

Epigenetics and Oxidative Stress in Aging
por: Guillaumet-Adkins, Amy, et al.
Publicado: (2017)

Imbalance between genomic gain and loss identifies high-risk neuroblastoma patients with worse outcomes
por: Fernández-Blanco, Beatriz, et al.
Publicado: (2020)

Genetic Instability and Intratumoral Heterogeneity in Neuroblastoma with MYCN Amplification Plus 11q Deletion
por: Villamón, Eva, et al.
Publicado: (2013)

Extracellular matrix composition defines an ultra-high-risk group of neuroblastoma within the high-risk patient cohort
por: Tadeo, Irene, et al.
Publicado: (2016)

Neuronal Differentiation-Related Epigenetic Regulator ZRF1 Has Independent Prognostic Value in Neuroblastoma but Is Functionally Dispensable In Vitro
por: Jiménez, Carlos, et al.
Publicado: (2021)

Heterogeneous MYCN amplification in neuroblastoma: a SIOP Europe Neuroblastoma Study
por: Berbegall, Ana P., et al.
Publicado: (2018)

Independent Validation of a Deep Learning nnU-Net Tool for Neuroblastoma Detection and Segmentation in MR Images
por: Veiga-Canuto, Diana, et al.
Publicado: (2023)

Frequency and Prognostic Impact of ALK Amplifications and Mutations in the European Neuroblastoma Study Group (SIOPEN) High-Risk Neuroblastoma Trial (HR-NBL1)
por: Bellini, Angela, et al.
Publicado: (2021)

The role of epigenetics and miRNAs in neuroblastoma development
por: Rupani, KV, et al.
Publicado: (2012)

Epigenetic state determines inflammatory sensing in neuroblastoma
por: Wolpaw, Adam J., et al.
Publicado: (2022)

The genomics and epigenetics of olfactory neuroblastoma: A systematic review
por: Kaur, Raman Preet, et al.
Publicado: (2021)

Identification of epigenetically regulated genes that predict patient outcome in neuroblastoma
por: Carén, Helena, et al.
Publicado: (2011)

Epigenetic Deregulation of MicroRNAs in Rhabdomyosarcoma and Neuroblastoma and Translational Perspectives
por: Romania, Paolo, et al.
Publicado: (2012)

Epigenetic regulation of the neuroblastoma genes, Arid3b and Mycn
por: Kobayashi, K, et al.
Publicado: (2013)

Antipsychotics function as epigenetic age regulators in human neuroblastoma cells
por: Du, Jianbin, et al.
Publicado: (2022)

High Oct4 expression: implications in the pathogenesis of neuroblastic tumours
por: Monferrer, Ezequiel, et al.
Publicado: (2019)

Expression of the neuron-specific protein CHD5 is an independent marker of outcome in neuroblastoma
por: Garcia, Idoia, et al.
Publicado: (2010)

Epigenetic alterations differ in phenotypically distinct human neuroblastoma cell lines
por: Yang, Qiwei, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_j2pv8gkf7m39juu9qg0n1sgg0k